Immunohistochemical profiling based on Bcl-2, CD10 and MUMI expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma

Journal of Pathology

Volumn 208, Issue 5, 2006, Pages 714-723

  Muris, J J F ^a   Meijer, C J L M ^a   Vos, W ^a   van Krieken, J H J M ^b   Jiwa, N M ^c   Ossenkoppele, G J ^a   Oudejans, J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Location Alkmaar   (Netherlands)

Author keywords

Algorithm; Bcl 2; CD10; Diffuse large B cell lymphoma; International prognostic index; MUMI; Stratification

Indexed keywords

CASPASE 9; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLICE INHIBITORY PROTEIN; INTERFERON REGULATORY FACTOR 4; MUM1 PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ALGORITHM; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GERMINAL CENTER; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON REGULATORY FACTORS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEPRILYSIN; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645238948     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1924     Document Type: Article

References (49)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. IARC Press: Lyon, 2001.
3. The International Non-Hodgkin's Lymphomas Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
5. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B cell lymphoma. N Engl J Med 2002;346(25):1937-1947.
6. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8(1):68-74.
7. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100(19):10585-10587.
8. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194(12):1861-1874.
9. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B cell lymphoma. Blood 2002;99:1136-1143.
10. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B cell lymphoma. Blood 2003;101(1):78-84.
11. Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E. Nordic Lymphoma Group Study. Immunohistochemical expression of CD23 and CD40 may identify prognostically favourable subgroups of diffuse large B cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res 2003;9(2):722-728.
12. Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, et al. Immunohistochemical expression patterns of germinal center and activation B cell markers correlate with prognosis in diffuse large B cell lymphoma. Am J Surg Pathol 2004;28(4):464-470.
13. Natkunam Y, Lossos IS, Taidi B, Zhao S, Lu X, Ding F, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B cell derivation. Blood 2005;105(10):3979-3986; E-pub 27 Jan 2005.
14. Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, et al. Evaluation of immunophenotype in diffuse large B cell lymphoma and its impact on prognosis. Mod Pathol 2005;E-pub ahead of print, 6 May 2005.
15. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
16. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomas de l'Adulte (GELA). Blood 1996;87:265-272.
17. Kramer MH, Hermans J, Parker J, et al. Clinical significance of Bcl-2 and p53 protein expression in diffuse large B cell lymphoma: a population-based study. J Clin Oncol 1996;14:2131-2138.
18. Muris JJ, Cillessen SA, Vos W, van Houdt IS, Kummer JA, van Krieken J, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B cell lymphomas. Blood 2004;E-pub ahead of print, 2 Dec 2004.
19. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haemotopoietic and lymphoid tissues. World Health Organization Classification of Tumours. IARC Press: Lyon, 2001.
20. Gospodarowicz MK, Sutcliffe SB. The extranodal lymphomas. Semin Radiat Oncol 1995;4:281-300.
21. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
22. Muris JJ, Meijer CJ, Cillessen SA, Vos W, Kummer JA, Bladergroen BA, et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B cell lymphomas. Leukemia 2004;18(3):589-596.
23. Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol Dis 2001;27:206-216.
24. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med. 2000;6:513-519.
25. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 1999;59:1693s-1700s.
26. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol 1999;17:781-828.
27. Wang J, Lobito AA, Shen F, Hornung F, Winoto A, Lenardo MJ. Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-Flip. Eur J Immunol 2000;30:155-163.
28. Hennino A, Berard M, Casamayor-Palleja M, Krammer PH, Defrance T. Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells. J Immunol 2000;165:3023-3030.
29. Hennino A, Berard M, Krammer PH, Defrance T. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J Exp Med 2001;193:447-458.
30. van Eijk M, Medema JP, de Groot C. Cutting edge: cellular Fas-associated death domain-like IL-1-converting enzyme-inhibitory protein protects germinal center B cells from apoptosis during germinal center reactions. J Immunol 2001;166:6473-6476.
31. Cox DR. Regression models and life Tables. J R Stat Soc Br 1972;34:187.
32. Armitage JO, Weisenberger DD, for the Non-Hodgkin's Lymphoma Classification Project. New approach to classifying non-Hodgkin's lymphomas. Clinical features of the major histologic subtypes. J Clin Oncol 1998;16:2780-2795.
33. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS. NF-κB anti-apoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-1683.
34. Chen C, Edelstein LC, Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000;20:2687-2695.
35. Piva R, Gianferretti P, Ciucci A, Taulli R, Belardo G, Santoro MG. 15-deoxy-δ-12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-κB activity and downregulation of anti-apoptotic proteins. Blood 2005;105(4):1750-1758. E-pub 21 Oct 2004.
36. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11(1):28-40.
37. Bairey O, Zimra Y, Shaklai M, Okon E, Rabizadeh E. Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B cell lymphomas. Clin Cancer Res 1999;5(10):2860-2866.
38. Kramer MH, Hermans J, Parker J, et al. Clinical significance of Bcl-2 and p53 protein expression in diffuse large B cell lymphoma: a population-based study. J Clin Oncol 1996;14:2131-2138.
39. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B cell lymphoma based on the expression of six genes. N Engl J Med 2004;350(18):1828-1837.
40. Rantanen S, Monni O, Joensuu H, Franssila K, Knuutila S. Causes and consequences of BCL2 overexpression in diffuse large B cell lymphoma. Leuk Lymphoma 2001;42:1089-1098.
41. Cutrona G, Leanza N, Ulivi M, Melioli G, Burgio VL, Mazzarello G, et al. Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. Blood 1999;94(9):3067-3076.
42. Cutrona G, Tasso P, Dono M, Roncella S, Ulivi M, Carpaneto EM, et al. CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL. Br J Cancer 2002;86(11):1776-1785.
43. Morabito F, Mangiola M, Rapezzi D, Zupo S, Oliva BM, Ferraris AM, et al. Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro. Haematologica 2003;88(8):864-873.
44. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23(18):4117-4126; E-pub 2 May 2005.
45. Schmits R, Schmitz N, Pfreundschuh M. German High-grade Non-Hodgkin's Lymphoma Study Group. The best treatment for diffuse large B cell lymphoma: a German perspective. Oncology (Williston Park) 2005;19(4):suppl 1 16-25.
46. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B cell lymphoma (DLBCL). Blood 2003;101(11):4279-4284.
47. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194(12):1861-1874.
48. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11(1):28-40.
49. Su TT, Guo B, Kawakami Y, Sommer K, Chae K, Humphries LA, et al. PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002;3(8):780-786.